12013
-
Research Reports in Clinical Cardiology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Galectin-3: clinical utility and prognostic value in patients with heart failure
Review
(1135) Total Article Views
Authors: Kramer F
Published Date February 2013
Volume 2013:4 Pages 13 - 22
DOI: http://dx.doi.org/10.2147/RRCC.S28562
| Received: |
06 December 2012 
|
|---|---|
| Accepted: | 03 January 2013 |
| Published: | 07 February 2013 |
Clinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, Germany
Abstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.
Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
-
Call For Submissions
Submit Original Research Article, Review, Case Report, or Rapid Communication in Research Reports in Clinical Cardiology
- The western diet and lifestyle and diseases of civilization
- Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
- Everolimus-eluting stents in interventional cardiology
- Stiffness of the large arteries in individuals with and without Down syndrome
